{
  "abstract": "Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. In an open label, phase 1 trial, ABBV-706, an antibody−drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/R SCLC only) and dose expansion (part 4, central nervous system tumors and high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 in R/R SCLC. In the monotherapy cohort ( N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg −1 and 70% at 2.5 mg kg −1 ). In the R/R SCLC monotherapy cohort ( n = 124), any-grade and grade 3 or higher TRAEs occurred in 93% and 61% of patients, respectively. ABBV-706 demonstrated promising preliminary efficacy in patients with R/R SCLC, with an objective response rate (ORR) of 52% (65/124). In patients with R/R SCLC receiving monotherapy in dose optimization and expansion part 2, ORR was similar between 1.8 mg kg −1 and 2.5 mg kg −1 doses (56% (23/41) and 59% (23/39), respectively), with a duration of response that was highest at the 1.8 mg kg −1 dose and with most patients achieving rapid and durable tumor reduction. Although exploratory, long-term efficacy measures were an important consideration in the RP2D determination, and in R/R SCLC monotherapy, overall survival (OS) was highest at the 1.8 mg kg −1 dose, with a median OS of 12.4 months. Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg −1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 .",
  "abstract_shown": true,
  "affiliations": [
    "The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lbyers@mdanderson.org",
    "Division of Medical Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea",
    "Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
    "Yale School of Medicine, New Haven, CT, USA",
    "National Cancer Center, Gyeonggi-do, Republic of Korea",
    "University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA",
    "University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA",
    "Washington University School of Medicine, St. Louis, MO, USA",
    "START San Antonio, San Antonio, TX, USA",
    "Department of Medicine, University of Chicago, Chicago, IL, USA",
    "Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain",
    "Vall d'Hebron Institute of Oncology, Barcelona, Spain",
    "Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel",
    "The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel",
    "Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea",
    "Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA",
    "Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea",
    "Department of Internal Medicine, Chonnam National University Medical School, and Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea",
    "Hospital Universitario 12 de Octubre and Universidad Complutense, Madrid, Spain",
    "Section of Hematology-Oncology, Department of Medicine, Hanyang University Medical Center, Hanyang University, Seoul, Republic of Korea",
    "National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan",
    "AbbVie Inc., North Chicago, IL, USA",
    "START Midwest, Grand Rapids, MI, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 31,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Lauren A. Byers",
      "orcid": "0000-0002-0780-2677"
    },
    {
      "affs": [
        1
      ],
      "name": "Byoung Chul Cho",
      "orcid": "0000-0002-5562-270X"
    },
    {
      "affs": [
        2
      ],
      "name": "Alissa Jamie Cooper",
      "orcid": "0000-0001-9124-0082"
    },
    {
      "affs": [
        3
      ],
      "name": "Anne C. Chiang",
      "orcid": "0000-0002-2111-4694"
    },
    {
      "affs": [
        4
      ],
      "name": "Ji‐Youn Han",
      "orcid": "0000-0001-5033-0006"
    },
    {
      "affs": [
        5
      ],
      "name": "Muhammad Furqan"
    },
    {
      "affs": [
        6
      ],
      "name": "Afshin Dowlati",
      "orcid": "0000-0003-4535-6839"
    },
    {
      "affs": [
        7
      ],
      "name": "Daniel Morgensztern",
      "orcid": "0000-0003-4349-2028"
    },
    {
      "affs": [
        8
      ],
      "name": "Kyriakos P. Papadopoulos",
      "orcid": "0000-0002-0667-2620"
    },
    {
      "affs": [
        9
      ],
      "name": "Noura J. Choudhury",
      "orcid": "0000-0002-5980-4973"
    },
    {
      "affs": [
        10,
        11
      ],
      "name": "María Vieito",
      "orcid": "0000-0001-7531-343X"
    },
    {
      "affs": [
        12,
        13
      ],
      "name": "Jair Bar",
      "orcid": "0000-0002-1224-3646"
    },
    {
      "affs": [
        14
      ],
      "name": "Joo-Hang Kim"
    },
    {
      "affs": [
        15
      ],
      "name": "Wallace Akerley",
      "orcid": "0000-0002-3090-4778"
    },
    {
      "affs": [
        16
      ],
      "name": "Tae Jeong Kim",
      "orcid": "0000-0001-6145-4426"
    },
    {
      "affs": [
        17
      ],
      "name": "Young‐Chul Kim",
      "orcid": "0000-0001-7019-7687"
    },
    {
      "affs": [
        18
      ],
      "name": "Luis G Paz-Ares",
      "orcid": "0000-0002-1947-3364"
    },
    {
      "affs": [
        19
      ],
      "name": "Myung‐Ju Ahn",
      "orcid": "0000-0002-5740-9654"
    },
    {
      "affs": [
        20
      ],
      "name": "Hiroshi Yokouchi",
      "orcid": "0000-0001-5964-0051"
    },
    {
      "affs": [
        21
      ],
      "name": "Darius Meiman",
      "orcid": "0000-0002-1005-9175"
    },
    {
      "affs": [
        21
      ],
      "name": "Wijith P. Munasinghe"
    },
    {
      "affs": [
        21
      ],
      "name": "Oluwadamilola Ogunyankin"
    },
    {
      "affs": [
        21
      ],
      "name": "Nadine S. Jahchan",
      "orcid": "0000-0002-0610-5001"
    },
    {
      "affs": [
        21
      ],
      "name": "Song Wang",
      "orcid": "0009-0004-7267-5848"
    },
    {
      "affs": [
        21
      ],
      "name": "Cristiano Ferlini",
      "orcid": "0000-0003-3886-9134"
    },
    {
      "affs": [
        21
      ],
      "name": "Randy R. Robinson",
      "orcid": "0000-0002-9503-1111"
    },
    {
      "affs": [
        21
      ],
      "name": "Frederick J. Kohlhapp",
      "orcid": "0009-0007-3132-5587"
    },
    {
      "affs": [
        21
      ],
      "name": "Tammy L. Palenski",
      "orcid": "0000-0003-0675-7728"
    },
    {
      "affs": [
        21
      ],
      "name": "Guillermo Rivell"
    },
    {
      "affs": [
        21
      ],
      "name": "Pooja Hingorani",
      "orcid": "0000-0002-4772-7456"
    },
    {
      "affs": [
        22
      ],
      "name": "Sreenivasa Chandana"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7anw8p89wpxep.bib",
  "cited_by": 12,
  "doi": "10.1038/s41591-026-04452-0",
  "fulltext_url": null,
  "id": "7anw8p89wpxep",
  "issns": [
    "1078-8956",
    "1546-170X",
    "1744-7933"
  ],
  "landing_url": "https://doi.org/10.1038/s41591-026-04452-0",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Lung Cancer Research Studies"
    ]
  ],
  "openalex": "W7163051937",
  "pdf_url": "https://www.nature.com/articles/s41591-026-04452-0.pdf",
  "pmcid": "PMC13472869",
  "pmid": "42225988",
  "published": "2026-06-01",
  "publisher": "Nature Portfolio",
  "ris": "https://research.draconitic.com/paper/7anw8p89wpxep.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T13:20:50Z",
      "native_id": "W7163051937",
      "source": "openalex",
      "url": "https://doi.org/10.1038/s41591-026-04452-0"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Lung Cancer Research Studies",
      "subfield": "oncology"
    }
  ],
  "title": "SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial",
  "title_text": "SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T13:20:50Z",
  "url": "https://research.draconitic.com/paper/7anw8p89wpxep",
  "venue": "Nature Medicine",
  "versions": []
}